Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Vanda Pharmaceuticals won a legal battle as a federal court overturned the FDA's rejection of Hetlioz for jet lag disorder, ...

Tonmya is the first new fibromyalgia therapy approved in over 15 years, targeting nonrestorative sleep to alleviate core ...

NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and ...

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

How a layered approach—tapping new avenues from earned media—can go a long way in boosting the brand engagement interplay ...

What is MFN in pharma? President Trump’s executive order on drug pricing states that the United States should be treated as a ...

As global director of healthcare and sciences at Google Cloud, Shweta Maniar is working with organizations to find ways to ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Eli Lilly is increasing Mounjaro's UK price by 170% to match European market levels, with the highest dose now costing £330.